MergerMay 15, 2026, 06:12 AM
Z Squared Inc. Completes Reverse Acquisition; Q1 Net Loss $(4.02M)
AI Summary
Coeptis Therapeutics Holdings, Inc. completed a reverse acquisition with Z Squared, Inc. on April 24, 2026, and subsequently changed its corporate name to Z Squared Inc. The company's principal business has shifted to digital asset mining, with most biopharmaceutical operations spun out. For the three months ended March 31, 2026, the company reported an increased net loss of $4,020,896, up from $3,420,941 in the prior year, despite sales increasing to $113,771. The company also noted substantial doubt about its ability to continue as a going concern.
Key Highlights
- Company changed name to Z Squared Inc. on April 24, 2026, following reverse acquisition.
- Completed reverse acquisition with Z Squared, Inc., shifting business to digital asset mining.
- Reported Q1 2026 net loss of $(4,020,896), up from $(3,420,941) in Q1 2025.
- Q1 2026 sales increased to $113,771 from $62,874 in Q1 2025.
- Total assets grew to $19,786,693 at March 31, 2026, from $16,153,921 at Dec 31, 2025.
- Accumulated deficit reached $113,870,346 as of March 31, 2026.
- Net cash used in operating activities was $(1,758,887) for Q1 2026.
- Company faces substantial doubt about its ability to continue as a going concern.